编者按：诱导接近（induced proximity）机制正在为新药开发提供一种不同于传统"占据靶点、抑制活性"的思路：通过药物将靶蛋白、E3连接酶、伴侣蛋白、抗体、受体或其他细胞效应系统拉近，重新塑造分子之间的空间关系，从而改变疾病相关靶点的功能或命运。2026年第二季度，诱导接近领域的最新进展呈现出以下趋势：

第一，首款蛋白降解靶向嵌合体获批，分子胶降解剂取得后期临床积极结果，显示靶向蛋白降解剂已经走向监管验证，并正从癌症向免疫炎症等更广泛疾病领域延伸。第二，RAS分子胶抑制剂和抗体偶联降解剂（DAC）等进展表明，诱导接近不再局限于"降解蛋白"，而是正在拓展为一种更广义的新药设计模式。第三，大药企合作和资本投入持续活跃，产业界对诱导接近药物的关注正在从经典蛋白降解剂扩展到更丰富的诱导接近技术平台和复杂分子形式。

面对这类药物在三元复合体形成、靶点选择性、递送、体内暴露、药效转化和CMC开发等方面的挑战，药明康德依托一体化、端到端的CRDMO赋能平台，构建了覆盖蛋白降解靶向嵌合体、分子胶、调节诱导接近靶向嵌合体、抗体偶联降解剂等多种分子类型的能力体系，为全球合作伙伴提供从早期发现、筛选、合成、分析纯化、测试到DMPK、生物分析和后续开发生产的系统支持，助力更多诱导接近药物加速走向临床、惠及患者。

首款蛋白降解靶向嵌合体获批，蛋白降解剂不再局限于癌症

2026年第二季度，诱导接近药物领域迎来重要里程碑。由辉瑞（Pfizer）和Arvinas联合开发的Veppanu（vepdegestrant）获得，用于治疗携带ESR1突变、ER阳性/HER2阴性晚期或转移性乳腺癌成人患者。这项批准的意义不只在于一款乳腺癌新药进入临床应用，更在于它证明了通过诱导靶蛋白与E3连接酶接近、进而实现靶向蛋白降解的药物设计理念，已经能够转化为监管机构认可的上市药品。

与此同时，分子胶类蛋白降解剂也在血液肿瘤领域继续获得积极临床结果。百时美施贵宝（Bristol Myers Squibb）在2026年美国临床肿瘤学会（ASCO）年会上公布了CELMoD药物mezigdomide联合carfilzomib和dexamethasone治疗复发或难治性多发性骨髓瘤的3期SUCCESSOR-2研究结果。与carfilzomib和dexamethasone对照方案相比，mezigdomide联合方案将疾病进展或死亡风险降低52%，中位无进展生存期（PFS）分别为18.0个月和8.3个月。该公司的另一款CELMoD药物iberdomide正在接受美国FDA审评，有望成为首个获批的CELMoD类药物。

值得一提的是，蛋白降解剂的应用范围已经不局限于实体瘤和血液肿瘤。Kymera Therapeutics在4月宣布，美国FDA授予其口服STAT6降解剂KT-621快速通道资格，用于治疗中重度嗜酸性粒细胞性哮喘。KT-621正在中重度嗜酸性粒细胞性哮喘和中重度特应性皮炎中开展2b期研究。

该公司与赛诺菲（Sanofi）联合开发的IRAK4靶向蛋白降解剂KT-485（SAR447971）正在1期临床试验中接受评估，用于治疗化脓性汗腺炎（HS）患者。Nurix Therapeutics的布鲁顿氏酪氨酸激酶（BTK）靶向蛋白降解剂bexobrutideg不仅在治疗慢性淋巴细胞白血病（CLL）的1期临床试验中达到83%的客观缓解率（ORR），也在早期临床研究中也显著降低皮肤中的BTK水平，支持其在慢性自发性荨麻疹等炎症和免疫疾病中的进一步探索。

这些进展共同说明，抗癌蛋白降解剂已经在后期临床开发和监管批准方面达到重要里程碑；在癌症之外，蛋白降解剂也有望进入免疫和炎症疾病、神经系统疾病等更广泛领域。对于转录因子、支架蛋白、耐药突变蛋白或具有非酶活性功能的靶点而言，"降解"可能比"抑制"提供更全面的功能调控方式。

RAS分子胶崛起，诱导接近不再局限于蛋白降解

然而，诱导接近并不止于"让致病蛋白被降解"。近年来进展迅速的RAS三元复合体抑制剂，正在把这一机制带向更广泛的靶点功能调控。

RAS长期以来被视为癌症治疗中极具挑战性的靶点。传统小分子抑制剂大多依赖于找到可结合口袋，并直接抑制靶点功能。而以Revolution Medicines的daraxonrasib为代表的新一代RAS抑制剂则采用了不同思路：它通过类似于分子胶的机制，诱导RAS蛋白、药物分子和cyclophilin A伴侣蛋白形成三元复合体，从而阻断RAS与下游效应蛋白的相互作用。

在今年的ASCO年会上，daraxonrasib的3期临床试验结果赢得了全场起立鼓掌。在3期RASolute 302研究中，daraxonrasib用于治疗既往接受过治疗的转移性胰腺导管腺癌（PDAC）患者。结果显示，与标准化疗相比，daraxonrasib显著改善总生存期（OS）和PFS。在意向治疗（ITT）人群中，daraxonrasib组的中位OS为13.2个月，化疗组为6.7个月。daraxonrasib组的中位PFS为7.2个月，化疗组为3.6个月。

该公司基于同样的分子胶机制开发的RAS G12D抑制剂zoldonrasib，近期在治疗转移性PDAC患者的早期临床研究中也显示出令人鼓舞的疗效。

其他公司也在利用分子胶作用机制开发RAS抑制剂。今年4月，Erasca公司公布了在研分子胶泛RAS抑制剂ERAS-0015在RAS突变实体瘤患者中的1期剂量递增试验初步数据。ERAS-0015在KRAS G12X非小细胞肺癌和KRAS G12X胰腺癌患者中观察到初步单药抗肿瘤活性。劲方医药（GenFleet Therapeutics）和贝达药业（Betta Pharmaceuticals）正在开发的泛RAS抑制剂也基于非降解分子胶作用机制，目前已经进入临床开发阶段。

这些RAS研发项目显示，诱导接近机制的核心并不等同于"降解"。它的本质是通过药物创造或稳定一个分子复合体，从而改变靶点的功能或稳定性。

大药企和资本持续加码，关注点从靶向蛋白降解扩展到广义诱导接近平台

诱导接近药物适应症和作用机制的拓展，也正在反映到产业合作和资本布局中。2026年第二季度，多项合作和融资事件显示，产业关注点已经不只局限于经典蛋白降解靶向嵌合体和肿瘤治疗领域，而是扩展到DAC、调节诱导接近靶向嵌合体等创新诱导接近平台，以及诱导接近药物在其他疾病领域的应用。

6月，罗氏（Roche）与Nurix Therapeutics达成全球合作，共同开发和商业化BTK降解剂bexobrutideg。根据协议，Nurix将获得7亿美元预付款，潜在交易总额最高达23亿美元。值得一提的是，双方联合开发的bexobrutideg的适应症不仅覆盖恶性血液肿瘤，还包括免疫疾病和神经系统疾病，体现了大药企对蛋白降解剂跨疾病领域开发潜力的重视。

罗氏在同一季度还与C4 Therapeutics围绕DAC开展了总额超过10亿美元的新研发合作。根据协议，C4 Therapeutics将利用其TORPEDO平台设计降解剂载荷，罗氏负责选择和设计抗体，并将抗体与降解剂载荷偶联。DAC将抗体的特异性靶向递送能力与降解剂载荷的催化作用机制相结合，有望将蛋白降解作用更精准地引导至特定肿瘤细胞或组织中，从而降低对正常组织的影响，并为高活性降解剂载荷提供更具选择性的递送方式。这一策略有望在提高疗效的同时拓宽治疗窗口。

资本市场也在继续支持探索更广泛诱导接近机制应用的公司。Flare Therapeutics在6月完成8500万美元C轮融资，并表示资金将用于推进靶向处于激活状态的雄激素受体的降解剂FX-111至概念验证阶段，同时推进靶向激活状态下雄激素受体的调节诱导接近靶向嵌合体项目的临床前开发。调节诱导接近靶向嵌合体是诱导接近机制在蛋白降解外的另一种应用。这类分子能够同时结合肿瘤特异性蛋白和另一种对细胞生存至关重要的蛋白，形成稳定的非天然三元复合物，从而破坏必需蛋白的功能，并选择性杀死癌细胞。

此外，FreeMind Investments和Daewoong Pharmaceutical在5月投资General Proximity。General Proximity试图系统性寻找能够调控疾病靶点的效应分子，并利用诱导接近机制将效应分子与靶点蛋白拉近。这些效应分子包括伴侣蛋白、衔接蛋白、运输蛋白、翻译后修饰相关蛋白等。将它们与靶点蛋白拉近，可能产生蛋白降解之外的多重生物学作用，包括蛋白激活、重折叠和细胞内重定位。General Proximity已在去年与第一三共（Daiichi Sankyo）达成研发合作；今年再次获得投资，也显示了产业界对诱导接近机制更广泛应用的兴趣。

从这些融资和合作可以看出，诱导接近不再只局限于靶向蛋白降解。大药企和资本关注的是更广泛的能力组合：如何发现可诱导的新复合体，如何选择最合适的效应系统，如何实现组织或细胞选择性，如何将复杂机制转化为可开发、可生产、可验证的候选药物。

一体化平台助力诱导接近药物开发

在靶向蛋白降解疗法十余年的产业转化历程中，药明康德几乎全程参与，为合作伙伴提供一体化赋能。在蛋白降解靶向嵌合体刚刚起步时，药明康德就前瞻性地布局相关能力和技术，搭建了集发现、合成、分析纯化和测试等能力于一体的一体化赋能平台，助力全球合作伙伴高效推进药物从早期发现到临床试验阶段。

药明康德一体化平台的能力不仅涵盖靶向蛋白降解分子，还包括分子胶以及多种新兴双功能分子。以分子胶药物发现为例，早期研发阶段中，无偏倚药物筛选的低命中率始终是一大挑战。为助力合作伙伴有效应对这一难题，药明康德采取了"双轨并进"的策略，构建起一套兼顾广度与深度的化合物库体系：一方面，通过多样化的DNA编码化合物库（DEL）大范围探索新靶点；另一方面，借助聚焦化合物库精细化研究已知蛋白体系，提升发现效率。

在分子胶药物的早期发现过程中，药明康德不仅依赖DNA编码化合物库进行筛选，还不断引入并整合多种先进技术，以助力合作伙伴拓展分子胶药物的发现能力。其中，亲和筛选质谱（ASMS）提供无标记筛选手段。药明康德构建了一个涵盖超过37万个小分子的广谱化合物库，通过比较这些分子在单蛋白与双蛋白条件下的质谱信号差异，精准识别出能够促进蛋白-蛋白相互作用的潜在分子胶候选物，从而识别出潜在促互作的小分子。

与此同时，公司还部署高通量筛选（HTS）技术。在"一孔一化合物"的自动化运行模式下，结合蛋白结合能力或降解能力等功能性实验，HTS能迅速锁定具备生物活性的候选分子，大幅提升筛选效率与准确性。通过将ASMS与HTS等多维筛选工具与DEL平台深度融合，药明康德打破了单一筛选方式的限制，让更多不同类型的靶点进入分子胶研究视野，进一步拓宽了分子胶在多类靶点上的研发空间。

伴随着新型靶向蛋白降解技术和诱导接近策略的持续涌现，药明康德紧跟科学前沿，迅速构建相关技术平台。如今，相关能力已涵盖蛋白降解靶向嵌合体、调节诱导接近靶向嵌合体、自噬靶向嵌合体、溶酶体靶向嵌合体、去泛素化酶靶向嵌合体、核糖核酸酶靶向嵌合体、磷酸化诱导嵌合小分子以及抗体偶联降解剂等主要分子类型。展望未来，药明康德将持续以一体化、端到端的CRDMO赋能平台，助力全球合作伙伴加速创新药物的研发生产进程，让科学突破更快为患者带来福祉。

Q2 2026 Review of Induced Proximity Drugs

The induced proximity mechanism offers a new way of thinking about drug discovery that differs from the traditional approach of "occupying a target and inhibiting its activity." By bringing target proteins, E3 ligases, chaperone proteins, antibodies, receptors, or other cellular effector systems into close proximity, drugs can reshape the spatial relationships between molecules and thereby alter the function or fate of disease-related targets. In the second quarter of 2026, the latest progress in the induced proximity field revealed several important trends.

First, the approval of the a "first-in-class" proteolysis targeting chimera, together with positive late-stage clinical results for molecular glue degraders, shows that targeted protein degraders have reached the stage of regulatory validation and are expanding from cancer into broader disease areas such as immunology and inflammation. Second, advances in RAS molecular glue inhibitors and degrader-antibody conjugates (DACs) suggest that induced proximity is no longer limited to "protein degradation," but is evolving into a broader drug design paradigm. Third, continued collaborations with major pharmaceutical companies and active capital investment show that industry interest in induced proximity medicines is expanding from classic protein degraders to a richer range of induced proximity platforms and complex molecular formats.

To address challenges such as ternary complex formation, target selectivity, delivery, in vivo exposure, pharmacodynamic translation, and CMC development, WuXi AppTec has built an integrated capability system covering multiple molecular types, including proteolysis targeting chimeras, molecular glues, regulated induced proximity targeting chimeras, and degrader-antibody conjugates. Supported by its integrated, end-to-end CRDMO enabling platform, WuXi AppTec provides global partners with systematic support spanning early discovery, screening, synthesis, analytical purification, testing, DMPK, bioanalysis, and subsequent development and manufacturing, helping accelerate more induced proximity medicines toward the clinic and ultimately benefit patients.

The First Proteolysis Targeting Chimera Approved; Protein Degraders Are No Longer Limited to Cancer

In the second quarter of 2026, the induced proximity drug field reached an important milestone. Veppanu (vepdegestrant), jointly developed by Pfizer and Arvinas, was approved by the U.S. FDA for the treatment of adult patients with ESR1-mutated, ER-positive/HER2-negative advanced or metastatic breast cancer. The significance of this approval goes beyond making a new breast cancer therapy available to patients.It demonstrates that the drug design concept of inducing proximity between a target protein and an E3 ligase to achieve targeted protein degradation can be translated into a marketed medicine recognized by regulatory authorities.

At the same time, molecular glue protein degraders continued to generate positive clinical results in hematologic malignancies. At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Bristol Myers Squibb announced Phase 3 SUCCESSOR-2 results for its CELMoD agent mezigdomide in combination with carfilzomib and dexamethasone for the treatment of relapsed or refractory multiple myeloma.Compared with the control regimen of carfilzomib and dexamethasone, the mezigdomide combination reduced the risk of disease progression or death by 52%, with median progression-free survival (PFS) of 18.0 months versus 8.3 months, respectively.Another CELMoD agent from the company, iberdomide, is currently under review by the U.S. FDA and may become the first approved CELMoD therapy.

Notably, the application of protein degraders is no longer limited to solid tumors and hematologic malignancies. In April, Kymera Therapeutics announced that the U.S. FDA had granted Fast Track designation to its oral STAT6 degrader KT-621 for the treatment of moderate-to-severe eosinophilic asthma. KT-621 is currently being evaluated in Phase 2b studies in moderate-to-severe eosinophilic asthma and moderate-to-severe atopic dermatitis, with topline results in atopic dermatitis expected by the end of this year. KT-485 (SAR447971), an IRAK4-targeted protein degrader being jointly developed by Kymera and Sanofi, is being evaluated in a Phase 1 clinical trial for patients with hidradenitis suppurativa (HS). Nurix Therapeutics’ Bruton’s tyrosine kinase (BTK) degrader bexobrutideg not only achieved an objective response rate (ORR) of 83% in a Phase 1 clinical trial for chronic lymphocytic leukemia (CLL), but also significantly reduced BTK levels in the skin in early clinical studies, supporting further exploration in inflammatory and immune diseases such as chronic spontaneous urticaria.

Together, these advances show that oncology-focused protein degraders have reached important milestones in late-stage clinical development and regulatory approval.Beyond cancer, protein degraders are also being explored in broader areas such as immune and inflammatory diseases and neurological disorders.For targets such as transcription factors, scaffold proteins, drug-resistant mutant proteins, or proteins with non-enzymatic functions, "degradation" may provide a more comprehensive way to modulate function than "inhibition."

The Rise of RAS Molecular Glues: Induced Proximity Is No Longer Limited to Protein Degradation

However, induced proximity is not limited to "degrading disease-causing proteins."Rapidly advancing RAS ternary complex inhibitors are extending this mechanism to broader modulation of target function.

RAS has long been viewed as one of the most challenging targets in cancer therapy. Traditional small-molecule inhibitors largely depend on identifying a druggable binding pocket and directly inhibiting target function. In contrast,next-generation RAS inhibitors such as Revolution Medicines’ daraxonrasib take a different approach: through a molecular glue-like mechanism, they induce the formation of a ternary complex comprising the RAS protein, the drug molecule, and the chaperone protein cyclophilin A, thereby blocking the interaction between RAS and downstream effector proteins.

At this year’s ASCO Annual Meeting, the Phase 3 clinical trial results of daraxonrasib received a standing ovation. In the Phase 3 RASolute 302 study, daraxonrasib was evaluated in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The results showed thatdaraxonrasib significantly improved overall survival (OS) and PFS compared with standard chemotherapy. In the intent-to-treat (ITT) population, median OS was 13.2 months in the daraxonrasib group and 6.7 months in the chemotherapy group.Median PFS was 7.2 months in the daraxonrasib group and 3.6 months in the chemotherapy group.

Zoldonrasib, the company’s RAS G12D inhibitor developed using the same molecular glue mechanism, has also recently shown encouraging efficacy in early clinical studies for patients with metastatic PDAC.

Other companies are also developing RAS inhibitors using molecular glue mechanisms. In April this year, Erasca announced preliminary data from the Phase 1 dose-escalation study of ERAS-0015, an investigational molecular glue pan-RAS inhibitor, in patients with RAS-mutant solid tumors. ERAS-0015 showed preliminary single-agent antitumor activity in patients with KRAS G12X non-small cell lung cancer and KRAS G12X pancreatic cancer. Pan-RAS inhibitors being developed by GenFleet Therapeutics and Betta Pharmaceuticals are also based on a non-degrading molecular glue mechanism and have entered clinical development.

These RAS programs show thatthe core of the induced proximity mechanism is not equivalent to "degradation." Its essence lies in using a drug to create or stabilize a molecular complex, thereby changing the function or stability of a target.

Major Pharmaceutical Companies and Investors Continue to Invest, Expanding Their Focus from Targeted Protein Degradation to Broader Induced Proximity Platforms

The expansion of induced proximity drugs in both indications and mechanisms is also reflected in industry collaborations and capital deployment. In the second quarter of 2026, multiple collaborations and financing events showed that industry interest is no longer limited to classic proteolysis targeting chimeras and oncology applications, but has expanded to innovative induced proximity platforms such as degrader-antibody conjugates and regulated induced proximity targeting chimeras, as well as applications of induced proximity drugs in other disease areas.

In June, Roche and Nurix Therapeutics entered into a global collaboration to jointly develop and commercialize the BTK degrader bexobrutideg. Under the agreement, Nurix will receive an upfront payment of $700 million, with the total potential deal value of up to $2.3 billion. Notably, the jointly developed bexobrutideg is intended not only for hematologic malignancies, but also for immune diseases and neurological disorders, reflecting major pharmaceutical companies’ recognition of the cross-disease development potential of protein degraders.

In the same quarter, Roche also entered into a new R&D collaboration with C4 Therapeutics focused on DACs, with a total value of more than $1 billion. Under the agreement, C4 Therapeutics will use its TORPEDO platform to design degrader payloads, while Roche will be responsible for selecting and designing antibodies and conjugating them with the degrader payloads.By combining the specific targeted delivery capability of antibodies with the catalytic mechanism of degrader payloads, DACs may direct protein degradation more precisely to specific tumor cells or tissues, thereby reducing effects on normal tissues and providing a more selective delivery approach for highly active degrader payloads.This strategy may help improve efficacy while broadening the therapeutic window.

Investors are also continuing to support companies exploring broader applications of induced proximity mechanisms. In June, Flare Therapeutics completed an $85 million Series C financing. The company said the proceeds will be used to advance FX-111, a degrader targeting the activated androgen receptor, toward proof of concept, while also supporting the preclinical development of its regulated induced proximity targeting chimera program for the activated androgen receptor.Regulated induced proximity targeting chimeras represent another application of induced proximity beyond protein degradation. These molecules can simultaneously bind a tumor-specific protein and another protein essential for cell survival, forming a stable, non-natural ternary complex that disrupts the function of the essential protein and selectively kills cancer cells.

In addition, FreeMind Investments and Daewoong Pharmaceutical invested in General Proximity in May. General Proximity aims to systematically identify effector molecules capable of regulating disease targets and to use induced proximity mechanisms to bring these effector molecules close to target proteins. These effector molecules include chaperone proteins, adaptor proteins, transport proteins, and proteins involved in post-translational modifications. Bringing them into proximity with target proteins may generate multiple biological effects beyond protein degradation, including protein activation, refolding, and intracellular re inducible new complexes localization. General Proximity entered into an R&D collaboration with Daiichi Sankyo last year; its additional investment this year also reflects industry interest in broader applications of induced proximity mechanisms.

Taken together, these financing and collaboration activities show that induced proximity is no longer limited to targeted protein degradation. Major pharmaceutical companies and investors are focusing on a broader set of capabilities: how to discover new inducible complexes, how to select the most appropriate effector systems, how to achieve tissue or cell selectivity, and how to translate complex mechanisms into developable and manufacturable drug candidates.

Integrated Platforms Help Advance the Development of Induced Proximity Drugs

Over more than a decade of targeted protein degradation development in the industry, WuXi AppTec has been deeply involved at every step, providing partners with fully integrated, end-to-end support. Even in the early days of proteolysis targeting chimera research, WuXi AppTec proactively invested in relevant capabilities, establishing a comprehensive platform that spans discovery, synthesis, purification, and testing.

WuXi AppTec’s integrated platform supports not only proteolysis targeting chimera development but also molecular glues and other bifunctional modalities. By uniting cutting-edge screening technologies, tailored library design, and deep scientific expertise, WuXi AppTec offers a fully integrated platform for molecular glue discovery. This approach supports partners across:

• Hit identification and validation

• Mechanistic characterization and degradation profiling

• Lead optimization and SAR development

With the continued emergence of innovative induced proximity technologies, WuXi AppTec remains closely aligned with the scientific frontier and has rapidly built related technology platforms. Today, its capabilities cover major molecular modalities including proteolysis targeting chimeras, regulated induced proximity targeting chimeras, autophagy-targeting chimeras, lysosome-targeting chimeras, deubiquitinase-targeting chimeras, ribonuclease-targeting chimeras, phosphorylation-inducing chimeric small molecules, and degrader-antibody conjugates. Looking ahead, WuXi AppTec will continue leveraging its integrated, end-to-end CRDMO enabling platform to help global partners accelerate the research, development, and manufacturing of innovative medicines—bringing scientific breakthroughs to patients more quickly.

参考资料：

[1] Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting. Retrieved July 2, 2026, from https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-presents-new-preclinical-and-phase-1/

[2] Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration. Retrieved July 2, 2026, from https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-first-participant-dosed-phase-1

[3] Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors. Retrieved July 2, 2026, from https://investors.erasca.com/news-releases/news-release-details/erasca-announces-positive-preliminary-phase-1-dose-escalation

[4] C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs). Retrieved July 2, 2026, from https://ir.c4therapeutics.com/news-releases/news-release-details/c4-therapeutics-expands-long-term-partnership-roche-through-new

[5] Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology. Retrieved July 2, 2026, from https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-announces-global-collaboration-roche-co

[6] FreeMind Investments and Daewoong Pharmaceutical Co., Ltd. Invest in General Proximity. Retrieved July 2, 2026, from https://www.generalproximity.bio/newsposts/freemind-investments-and-daewoong-pharmaceutical-co-invest-in-general-proximity

[7] Flare Therapeutics Secures $85M in Insider-Led Series C Financing and Appoints Anna Protopapas as Chief Executive Officer. Retrieved July 2, 2026, from https://www.flaretx.com/flare-therapeutics-secures-85m-in-insider-led-series-c-financing-and-appoints-anna-protopapas-as-chief-executive-officer/

免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复"转载"，获取转载须知。